Sanuwave preliminary Q2 2026 revenue tops raised guidance range

Sanuwave Health, Inc. (NASDAQ: SNWV) said on July 13, 2026 that preliminary, unaudited revenues for the second quarter ended June 30, 2026 are expected to be in the range of $9.6 million to $9.8 million, above the high end of the company's revised guidance range of $8.5 to $9.5 million that had been issued on June 16, 2026.¹

That preliminary figure marks a decline from a year earlier: the second quarter results represent a decrease of approximately 3 to 5 percent from revenues of $10.1 million in the second quarter of 2025.¹

CEO Morgan Frank said the quarter came in above the top of the range laid out in June, with the business playing out largely as forecast, as capital sales faced headwinds from stress in the company's customer base and from sales of used Ultramist systems in its market¹. Frank said the company has been working to qualify, train, and support new users of secondhand devices, and is offering trade-in terms so that used units can be exchanged for certified pre-owned systems carrying a manufacturer's warranty¹, adding that this program has been showing success so far¹.

On the product side, Frank said sales of consumable applicators set all-time records for both unit sales and revenues, by significant margins¹, which he characterized as a sign of growing confidence in Ultramist as a wound care option and, given the consumables-driven business model, as a positive indicator going forward.

The company said it will discuss the quarter further when it reports full Q2 earnings in August 2026.¹ Sanuwave cautioned that the preliminary figures are based on management's initial analysis and may be adjusted once the quarter-end financial close and review procedures are completed.¹ The release did not include cash position or runway figures.